Unlock Pathway Codes, Reshape Cancer Fight
Professor BENJAMIN YAT-MING YUNG, former Professor in the Department of Pharmacology at Chang Gung University College of Medicine, draws on forty years of accumulated research on NPM1/B23 to present the world's first network model of cancer drug resistance and recurrence pathways.
This book breaks free from traditional therapy frameworks, delving into the four major characteristics of cancer to reveal the core pathogenesis of nucleolar imbalance and analyze the regulatory mechanisms of seven key pathway categories. The breakthrough QGCT® deconstructs personalized dysregulated pathways for patients, while providing pathway-based supplement applications and clinical solutions.
More than just a popular science introduction to cancer knowledge, it offers patients new directions in precision treatment and provides scientific prevention strategies for health-conscious individuals. By integrating cutting-edge science with personalized care, it transforms the arduous journey of fighting cancer into a clear, navigable path to recovery.
From historical foundations to contemporary innovations, from data interpretation to clinical application-this book charts a visionary path toward a future in which cancer therapy is not only more effective, personalized, but also more compassionate.
Professor Kwong-Kwok Wong, the MD Anderson Cancer Center
A testament to how an unwavering pursuit of scientific ideals, grounded in conviction and passion, can lead to transformative breakthroughs in medicine.
Yu-Sun Chang, Ph.D., Professor, Chang Gung University
This book represents the culmination of decades of thoughtful research and genuine care for cancer patients. It offers hope grounded in rigorous science—exactly what our field and our patients need.
Jason Lih, Ph.D., Vice President of R&D, Apeximmune Therapeutics
BENJAMIN YAT-MING YUNG
Professor Benjamin Yat-Ming Yung is a distinguished scientist and educator, trained at world-renowned institutions, including Stanford University. His decades of research on the nucleolar protein NPM1/B23 have now culminated in the world's first pathway network model for cancer drug resistance and recurrence, unlocking new possibilities in precision oncology and offering hope to millions worldwide. This book distills his revolutionary insights, blending cutting-edge science with a transformative, personalized approach to cancer care.